Page 1 of 1

Novartis announces positive results for Siponimod

Posted: Thu Aug 25, 2016 1:07 am
Novartis AG has said that a late-stage study has shown the oral, once-daily BAF312 drug, or Siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis...Read more - ... mod-250816